Good outcomes with dexamethasone implant for persistent macular edema from uveitis or Irvine-Gass syndrome

Researchers analyzed a subset of 40 patients who participated in a large prospective, multi-center trial that randomized patients with persistent macular edema due to a variety of causes to treatment with a 350 µm or 700 µm dexamethasone biodegradable implant or to observation. Among the subset of patients with uveitis or Irvine-Gass syndrome, 41.7 percent of the 350 µm group and 53.8 percent in the 700 µm group had a 10-letter improvement in BCVA at day 90, compared with only 14.3 percent in the control group. The treated group also experienced a statistically significant improvement in fluorescein leakage, and the implant was well-tolerated.